glp 1 pet scan GLP-1 Drug Use May Create New Challenges in Cancer Imaging New PET tracer improves detection

Semaglutide injections belong to a class of medications known as incretin mimetics

While gallbladder problems can happen to anyone taking GLP-1 medications, certain factors may increase your risk

All GLP-1 medications follow dose-escalation protocols over 416 weeks to minimise gastrointestinal side effects such as nausea and vomiting

Toxicity of glutathione-binding metals: a review of targets and mechanisms

Common adverse effects of GLP-1 receptor agonists include: Gastrointestinal symptoms (nausea, vomiting, diarrhoea, constipation) Injection site reactions Headache Fatigue Dizziness Important safety considerations include: Risk of hypoglycaemia when used with insulin or sulfonylureas (dose reduction of these agents may be needed) Potential worsening of diabetic retinopathy with semaglutide in patients with pre-existing retinopathy [18] Risk of dehydration and acute kidney injury from persistent vomiting or diarrhoea Pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies, though human relevance remains uncertain) [19] [20] Patients should be counselled about persistent severe abdominal pain as a potential warning sign of pancreatitis requiring immediate medical attention